HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Rapid Response to:

In Brief: Robin Goldman and Henry M. Adam Escherichia coli Pediatrics in Review 2006; 27: 114-115 [Full text] [PDF]

Rapid Responses: Submit a response to this article

Rapid Responses published:

CLARIFICATION FOR JUNE 2006 ISSUE

lawrence f nazarian   (21 April 2006)

CLARIFICATION FOR JUNE 2006 ISSUE 21 April 2006
lawrence f nazarian, editor PIR Send letter to journal: Re: CLARIFICATION FOR JUNE 2006 ISSUE sydney_sutherland{at}urmc.rochester.edu lawrence f nazarian	In the March issue of Pediatrics in Review, in the comment at the end of the "In Brief" article on Escherichia coli, trimethoprim/sulfamethoxazole is listed as an effective agent in preventing traveler's diarrhea, reflecting information in the current edition (2003) of the Red Book on infectious diseases of the American Academy of Pediatrics (1). Dr. John Gallagher has pointed out that because of increased resistance - a problem mentioned in the comment by Dr. Adam - that agent is no longer effective against the organisms that cause traveler's diarrhea. The predominant point made by Dr. Adam, which bears emphasis, is that prophylaxis against traveler's diarrhea with any agent is not recommended for most people. Instead, prevention through care in choosing what to ingest is the best policy, and early treatment of diarrhea is effective. Currently, azithromycin is recommended as the drug of choice for treatment of traveler's diarrhea. (1) Committee on Infectious Diseases. American Academy of Pediatrics. Red Book: 2003 Report on the Committee on Infectious Diseases. 26th Edition. Elk Grove Village, IL: American Academy of Pediatrics. 20003 LFN Conflict of Interest: None declared